2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 278-282
Treatment Considerations, Supportive Care, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

732 A pilot randomized controlled trial of a fear of cancer recurrence intervention for lymphoma survivors

Miryam Yusufov, PhD, Angel M. Cronin, M.S.2, Molly Ream, PhD3, Cristina Pozo-Kaderman, PhD4, Benjamin Sankel, BA5, Andrew Hantel, MD, MPH6, Jennifer Mack, MD, MPH7, Ann LaCasce, MD, MMSc8, Gregory A. Abel, MD, MPH9, Oreofe Odejide, MD, MPH10
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

INTRODUCTION: Fear of cancer recurrence (FCR), defined as the “fear, worry, or concern relating to the possibility that cancer will come back or progress,” (Lebel, Cancer 2016) affects more than 50% of lymphoma survivors. Patients with clinically significant FCR are more likely to experience poor quality of life (QOL), anxiety, and depression compared to those without FCR (Koch L, Psychooncology 2014). Despite its negative impact, there is a paucity of effective interventions to address FCR for lymphoma survivors.

 METHODS: We conducted a pilot randomized controlled trial comparing an FCR intervention: Understand and Prevail: Lymphoma Fear of Cancer Recurrence Therapy (UPLYFT) to usual care in lymphoma survivors who were ≥ 18 years, 3-24 months from completing first-line lymphoma treatment, in complete remission, and had clinically significant FCR (score of ≥ 16 on the severity subscale of the fear of cancer recurrence inventory [FCRI; Simard, Support Care Cancer, 2009]). Randomization was 1:1 and stratified by lymphoma type (aggressive non-Hodgkin lymphoma [NHL], indolent NHL, and Hodgkin lymphoma). We developed UPLYFT as a weekly virtually delivered 6-session structured intervention combining lymphoma-specific education with acceptance and commitment therapy (ACT) principles. Each session lasted 30 minutes and was delivered by trained psychologists. Unlike traditional psychological interventions focused on symptom reduction, ACT supports individuals in coping with distress related to potential situations that may not be modifiable such as lymphoma recurrence. We refined UPLYFT through interviews with psychologists and lymphoma clinicians (n=8) and a field test with lymphoma survivors (n=6). Participants completed questionnaires assessing FCR, QOL (QOL-Cancer Survivor instrument), anxiety, and depression (Hospital Anxiety and Depression Scale) at baseline, 3 weeks/mid-intervention, 6 weeks/post-intervention, and at 18 weeks/12 weeks post-intervention. The primary outcome was feasibility (≥50% enrollment of eligible patients approached; ≥70% completion of intervention sessions and patient-reported data collection). Secondary outcomes were acceptability (≥90% satisfaction rate, ≤10% disenrollment rate), and preliminary efficacy (FCR, QOL, anxiety, and depression scores). T-tests were used to compare between-group mean differences in change scores at 6 weeks versus baseline for UPLYFT and usual care participants.

RESULTS: Sixty participants were randomized to UPLYFT (n=30) and usual care (n=30) arms. Median age was 50 years (IQR 35, 65) and 53% were female. Of the study cohort, 5.0% were Asian, 3.3% Black or African American, and 92% White; 8.2% were Hispanic/Latino. Among 63 eligible patients, 60 (95%) enrolled. Of all enrollees, 4 (6.7%) withdrew from the study (reasons: scheduling challenges, overwhelmed at thought of confronting FCR, not feeling much FCR anymore). Of participants randomized to UPLYFT, 23 (77%) completed all six sessions; of all participants, 45 (75%) completed questionnaires at all time points. Among the 23 UPLYFT participants who completed all six sessions, 20 completed satisfaction surveys at the end of the intervention; 100% (20/20) were mostly or very satisfied with the intervention (87% based on denominator of 23) and 95% (19/20) would generally or definitively recommend the intervention if a friend needed similar help (83% based on a denominator of 23). At 6 weeks, compared to baseline, UPLYFT participants reported lower FCR (mean difference [MD] = -12.7, 95% Confidence Interval [CI] -23.7, -1.76, p =0.02), lower anxiety (MD = -1.70, 95%CI -3.16, -0.24, p =0.02), and lower depression (MD = -1.27, 95%CI -2.69, 0.22; p=0.09) compared to usual care. Change in QOL was similar between both groups at 6 weeks (MD=0.22, 95% CI -0.29, 0.73; p =0.38).

CONCLUSIONS: UPLYFT was feasible in this cohort of lymphoma survivors. Although satisfaction was high among intervention participants who completed study surveys, the overall rate was slightly lower than our a priori threshold when including non-responders. UPLYFT also demonstrated encouraging preliminary effects on FCR and anxiety compared to usual care. Our results highlight the promise of an ACT-based intervention to manage FCR among lymphoma survivors and support a future efficacy trial.

 

Oreofe Odejide, MD, MPH: No relevant conflicts of interest to declare.